Invasive pulmonary aspergillosis due to a multi-azole resistant Aspergillus fumigatus

Acta Clinica Belgica

Volumn 67, Issue 1, 2011, Pages 46-48

  Jeurissen, A ^a   Cooreman, S ^a   Van Kerckhoven, W ^a   Van Leemput, J ^a   Vanhove, P ^a   Lagrou, Katrien ^b   Heytens, L ^a  

^a GZA St Augustinus ^*  (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B; CIPROFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; VORICONAZOLE;

ADULT; ANAMNESIS; ANTIBIOTIC RESISTANCE; ARTICLE; ASPERGILLUS FUMIGATUS; CASE REPORT; CHRONIC NECROTIZING PULMONARY ASPERGILLOSIS; CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; LOADING DRUG DOSE; LUNG ASPERGILLOSIS; LUNG BIOPSY; MALE; PNEUMONIA;

ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; AZOLES; DRUG RESISTANCE, MULTIPLE, FUNGAL; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; MALE; MIDDLE AGED;

EID: 84862577621     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.2143/ACB.67.1.2062627     Document Type: Article

References (20)

1. Segal BH. Medical progress: Aspergillosis. N Engl J Med 2009; 360: 1870-1884.
2. Patterson TF. Risk stratification for invasive aspergillosis: early assessment of host susceptibility. Med Mycol 2009; 47: S255-260.
3. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the infectious disease society of America. Clin Infect Dis 2008; 46: 327-360.
4. Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med 2007; 356: 1481-1483.
5. Howard SJ, Arendrup MC. Aqcuired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. Med Mycol 2010; early online: 1-6.
6. Snelders E, Karawajczyk A, Schaftrenaar G, Verweij PE, Melchers WJ. Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. Antimicrob Agents Chemother 2010; 54: 2425-2430.
7. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
8. Pasqual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycosis improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-211.
9. Miyakis S, Van Hal SJ, Marriott D. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect 2010; 16: 927-933.
10. Smith J, Safdar N, Knasinski V, Bhavnani SM, Ambrose PG, Andes D. Voriconazole Therapeutic Drug Monitoring. Antimicrob Agents Chemother 2006; 50: 1570-1572.
11. Da Silva Ferreira ME, Colombo AL, Paulsen I, et al. The ergosterol biosynthesis pathway, transporter genes, and azole resistance in Apsergillus fumigatus. Med Mycol 2005; 43: S313-319.
12. Mellado E, Alcazar-Fuoli L, Garcia-Effron G, Alastruey-Izquerido A, Cuenca- Estrella M, Rodriguez-Tudela JL. New resistance mechanisms to azole drugs in Aspergillus fumigatus and emergence of antifungal drugs-resistant A. fumigatus atypical strains. Med Mycol 2006: 44; S367-371.
13. Blueid A, Howard SJ, Moore CB, et al. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J Antimicrob Chemother 2010; 65: 2116-2118.
14. Snelders E, Van der Lee HA, Kuijpers J. et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. Plos Med 2008: 5; e219.
15. Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009; 15: 1068-1076.
16. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis 2009; 9: 789-795.
17. Snelders E, Huis in 't Veld RA, et al. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol 2009; 75: 4053-4057.
18. Van der Linden J, Warris A, Van der Meer J, Bresters D, Melchers WJ, Verweij PE. Azoolresistente invasieve aspergillose. Ned Tijdschr Geneeskd 2009; 153: 1-7.
19. rd Advances Against Aspergillosis, Florida, 2008.
20. Maertens J, Raad I, Petrikkos G, et al. Efficacy and Safety of Caspofungin for Treatment of Invasive Aspergillosis in Patients Refractory to or Intolerant of Conventional Antifungal Therapy. Clin Infect Dis 2004; 39: 1563-1571.